Minnow Street Minnow Street
Buy Day today: Poor Neutral (49) Good Mixed market breadth · no major macro event

biote Corp (BTMD)

Healthcare Medical Care Facilities
2.50 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock

Basics

Market Cap
0.1Mrd. $
Shares Outstanding
30Mio.
Float
64.7%
Beta
1.7

Performance

Perf. 1M
-18.10%
Perf. 3M
26.50%
Perf. 6M
-39.70%
YTD Performance (%)
-17.30%
52-Week-High Distance
-58.7%

Valuation

P/E
4.2
Forward P/E
5.6
PEG
P/B
3.0
P/S
0.4
EV/EBITDA
4.4
Price/FCF
2.6

Profitability

Gross Margin
70.1%
EBIT Margin
Net Margin
8.3%
Return on Equity
0.0%
Return on Assets
17.8%

Balance Sheet & Safety

Equity Ratio
negative equity
Debt/Equity
-1.9
Altman Z
4.26
Piotroski
5 von 9

Growth

Sales Growth Last Quarter
-8.30%
EPS Growth Last Quarter
-83.80%
Sales Growth (Year)
-2.52%
Forward Sales Growth
6.69%
Forward EPS Growth
21.30%

Quality & Screener

Stage
4
RS Rating
27
EPS Rating
5
Piotroski
5 von 9
Fundamental Rating
D (-16 von 100)
Altman Z
4.26

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Sales Per Quarter ($M)
2024: Q4 · 49.8 Mio. $ Q4 2025: Q1 · 49.0 Mio. $ Q1 2025: Q2 · 48.9 Mio. $ Q2 2025: Q3 · 48.0 Mio. $ Q3 2025: Q4 · 46.4 Mio. $ Q4 2026: Q1 · 44.9 Mio. $ Q1
Earnings Per Share Per Quarter ($)
2024: Q4 · 0.12 $ Q4 2025: Q1 · 0.45 $ Q1 2025: Q2 · 0.11 $ Q2 2025: Q3 · 0.27 $ Q3 2025: Q4 · 0.06 $ Q4 2026: Q1 · 0.08 $ Q1
Net Margin Per Quarter (%)
2024: Q4 · 7.4 % Q4 2025: Q1 · 28.0 % Q1 2025: Q2 · 6.5 % Q2 2025: Q3 · 17.1 % Q3 2025: Q4 · 4.2 % Q4 2026: Q1 · 5.1 % Q1
Operating Cash Flow Per Quarter ($M)
2024: Q4 · 12.4 Mio. $ Q4 2025: Q1 · 6.5 Mio. $ Q1 2025: Q2 · 7.1 Mio. $ Q2 2025: Q3 · 14.1 Mio. $ Q3 2025: Q4 · 7.6 Mio. $ Q4 2026: Q1 · 3.9 Mio. $ Q1
Free Cash Flow Per Quarter ($M)
2024: Q4 · 11.3 Mio. $ Q4 2025: Q1 · 4.8 Mio. $ Q1 2025: Q2 · 5.3 Mio. $ Q2 2025: Q3 · 13.4 Mio. $ Q3 2025: Q4 · 6.5 Mio. $ Q4 2026: Q1 · 2.7 Mio. $ Q1
Sales Growth vs. Year-Ago Quarter (%)
2024: Q4 · 9.0 % Q4 2025: Q1 · 4.7 % Q1 2025: Q2 · -0.6 % Q2 2025: Q3 · -6.7 % Q3 2025: Q4 · -6.9 % Q4 2026: Q1 · -8.3 % Q1
EPS Growth vs. Year-Ago Quarter (%)
2024: Q4 · -52.1 % Q4 2025: Q3 · -23.5 % Q3 2025: Q4 · -47.2 % Q4 2026: Q1 · -83.4 % Q1
Price Change in Quarter (%)
2024: Q4 · 10.8 % Q4 2025: Q1 · -46.1 % Q1 2025: Q2 · 20.7 % Q2 2025: Q3 · -25.4 % Q3 2025: Q4 · -13.3 % Q4 2026: Q1 · -48.1 % Q1

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.12 -52.10 50 9.00 7.40 12 11
2025: Q1 0.45 49 4.70 28.00 7 5
2025: Q2 0.11 49 -0.60 6.50 7 5
2025: Q3 0.27 -23.50 48 -6.70 17.10 14 13
2025: Q4 0.06 -47.20 46 -6.90 4.20 8 7
2026: Q1 0.08 -83.40 45 -8.30 5.10 4 3
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

biote Corp. ist im Bereich Praxisaufbau im Segment der Hormonoptimierung tätig.

Employees223
HeadquartersIrving, TX
Websitebiote.com
IPO Date28. Apr 2021
Next Earnings5. Aug 2026

Management

Management
Name Title Birth Year
Marc D. Beer Executive Chairman 1965
Robert C. Peterson Interim CEO, CFO, Chief Business Officer & Director 1977
John J. Olsen Chief Information Officer 1957
Dan Monico General Counsel
Joel Pickering Chief Marketing Officer
Richard Kevin Key Chief Digital Officer 1971
Jade Beutler Head of Nutraceuticals 1964
Cory Rice D.O. Chief Clinical Advisor & Member of Medical Advisory Board
Joey Lopes SVP of Strategy & Commercial Operations
Komal Bajaj M.D., M.S. Chief Medical Officer

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?